Positron-emission tomography imaging of the TSPO with [18F]FEPPA in a preclinical breast cancer model

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 3, 2013, Pages 254-259

  Vasdev, Neil ^a,b   Green, David E ^c   Vines, Douglass C ^c,d   McLarty, Kristin ^b   McCormick, Patrick N ^a,b   Moran, Matthew D ^a,b   Houle, Sylvain ^a,b   Wilson, Alan A ^a,b   Reilly, Raymond M ^b,d,e  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

18F FEPPA; Automation; Breast cancer; Fluorine 18; Peripheral benzodiazepine receptor; Positronemission tomography; Translocator protein; TSPO

Indexed keywords

BENZODIAZEPINE RECEPTOR; N [2 (2 FLUOROETHOXY)BENZYL] N (4 PHENOXYPYRIDIN 3 YL)ACETAMIDE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER MODEL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG UPTAKE; EX VIVO STUDY; HEART; MOUSE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RADIOACTIVITY; SPLEEN; TUMOR XENOGRAFT;

ANILIDES; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FLUORINE RADIOISOTOPES; HETEROGRAFTS; HUMANS; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIOPHARMACEUTICALS; RECEPTORS, GABA;

EID: 84876143204     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1196     Document Type: Article

References (44)

1. Verma A, Facchina SL, Hirsch DJ, et al. Photodynamic tumor therapy: Mitochondrial benzodiazepine receptors as a therapeutic target. Mol Med 1998;4:40
2. Schlichter R, Rybalchenko V, Poisbeau P, et al. Modulation of GABAergic synaptic transmission by the non-benzodiazepine anxiolytic etifoxine. Neuropharmacology 2000;39:1523
3. Bono F, Lamarche I, Prabonnaud V, et al. Peripheral benzodiazepine receptor agonists exhibit potent antiapoptotic activities. Biochem Biophys Res Commun 1999;265:457
4. Benavides J, Quarteronet D, Imbault F, et al. Labelling of ''peripheral-type'' benzodiazepine binding sites in the rat brain by using [3H]PK 11195, an isoquinoline carboxamide derivative: Kinetic studies and autoradiographic localization. J Neurochem 1983;41:1744
5. Tallman JF, Thomas JW, Gallager DW. GABAergic modulation of benzodiazepine binding site sensitivity. Nature 1978;274:383
6. Anholt RR, Murphy KM, Mack GE, et al. Peripheral-type benzodiazepine receptors in the central nervous system: Localization to olfactory nerves. J Neurosci 1984;4:593
7. Beard CM, Waring SC, O'Brien PC, et al. Nonsteroidal antiinflammatory drug use and Alzheimer's disease: A casecontrol study in Rochester, Minnesota, 1980-1984. Mayo Clin Proc 1998;73:951
8. Cymerman U, Pazos A, Palacious JM. Evidence for species differences in ''peripheral'' benzodiazepine receptors: An autoradiographic study. Neurosci Lett 1986;66:153
9. Maaser K, Sutter AP, Scherübl H. The peripheral benzodiazepine receptor: A target for innovative diagnostic and therapeutic approaches in gastrointestinal oncology. Cancer Ther 2004;2:345
10. Hardwick M, Fertikh D, Culty M, et al. Peripheral-type benzodiazepine receptor (PBR) in human breast cancer: Correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol. Cancer Res 1999;4:831
11. Beinlich A, Strohmeier R, Kaufmann M, et al. Relation of cell proliferation to expression of peripheral benzodiazepine receptors in human breast cancer cell lines. Biochem Pharmacol 2000;60:397
12. Hardwick M, Rone J, Han ZQ, et al. Peripheral-type benzodiazepine receptor levels correlate with the ability of human breast cancer MDA-MB-231 cell line to grow in SCID mice. Int J Cancer 2001;94:322
13. Han ZQ, Slack RS, Li W, et al. Expression of peripheral benzodiazepine receptor (PBR) in human tumors: Relationship to breast, colorectal, and prostate tumor progression. J Recept Signal Transduct Res 2003;23:225
14. Zheng J, Boisgard R, Siquier-Pernet K, et al. Differential expression of the 18 kDa translocator protein (TSPO) by neoplastic and inflammatory cells in mouse tumors of breast cancer. Mol Pharmacol 2011;8:823
15. Hunakova L, Bodo J, Chovancova J, et al. Expression of new prognostic markers, peripheral-type benzodiazepine receptor and carbonic anhydrase IX, in human breast and ovarian carcinoma cell lines. Neoplasma 2007;54:541
16. American Cancer Society. Cancer Facts and Figures. Atlanta: American Cancer Society, 2009
17. Laoui D, Movahedi K, Overmeire EV, et al. Tumor-associated macrophages in breast cancer: Distinct subsets, distinct functions. Int J Dev Biol 2011;55:861
18. Pappata S, Levasseur M, Gunn RN, et al. Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK1195. Neurology 2000;55:1052
19. Banati RB, Goerres GW, Myers R, et al. [11C]-(R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen's encephalitis. Neurology 1999;53:2199
20. Cagnin A, Myers R, Gunn RN, et al. [11C]-(R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain 2001;124: 2014
21. Turner MR, Cagnin A, Turkheimer FE, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: An [11C]-(R)-PK11195 positron emission tomography study. Neurobiol Dis 2004;15:601
22. Gerhard A, Banati RB, Goerres GB, et al. [11C]-(R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 2003;61:686
23. Pappata S, Cornu P, Samson Y, et al. PET study of carbon- 11-PK 11195 binding to peripheral type benzodiazepine sites in glioblastoma: A case report. J Nucl Med 1991;32:1608
24. Sauvageau A, Desjardins P, Lozeva V, et al. Increased expression of ''peripheral-type'' benzodiazepine receptors in human temporal lobe epilepsy: Implications for PET imaging of hippocampal sclerosis. Metab Brain Dis 2002;17:3
25. Chauveau F, Boutin H, Van Camp N, et al. Nuclear imaging of neuroinflammation: A comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging 2008;35:2304
26. Dollé F, Luus C, Reynolds A, et al. Radiolabelled molecules for imaging the translocator protein (18 kDa) using positron emission tomography. Curr Med Chem 2009;16:2899
27. Luus C, Hanani R, Reynolds A, et al. The development of PET radioligands for imaging the translocator protein 18 kDa: What have we learned? J Labelled Compd Radiopharm 2010;53:501
28. Quon A, Gambhir SS FDG-PET and beyond: Molecular breast cancer imaging. J Clin Oncol 2005;23:1664
29. Pantaleo MA, Nannini M, Maleddu A, et al. Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat Rev 2008;34:103
30. Wilson AA, Garcia A, Parkes J, et al. Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. Nucl Med Biol 2008;35:305
31. van Oosten EM, Wilson AA, Stephenson KA, et al. An improved radiosynthesis of the muscarinic M2 radiopharmaceutical, [18F]FP-TZTP. Appl Radiat Isot 2009;67:611
32. Vines DC, Green DE, Kudo G, et al. Evaluation of mouse tail-vein injections both qualitatively and quantitatively on small-animal PET tail scans. J Nucl Med Technol 2011; 39:264
33. Rusjan PM, Wilson AA, Bloomfield PM, et al. Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography. J Cereb Blood Flow Metab 2011;31:1807
34. Wyatt SK, Manning HC, Bai M, et al. Molecular imaging of the translocator protein (TSPO) in a pre-clinical model of breast cancer. Mol Imaging Biol 2010;12:349
35. McLarty K, Fasih A, Scollard DA, et al. 18F-FDG smallanimal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice. J Nucl Med 2009;50:1848
36. Brown AK, Fujimura Y, Liow J-S, et al. Radiation dosimetry and biodistribution in monkey and man of 11C-PBR28: A PET radioligand to image inflammation. J Nucl Med 2007;48: 2072
37. Ching ASC, Kuhnast B, Damont A, et al. Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases. Insights Imaging 2012;3:111
38. Owen DR, Gunn RN, Rabiner EA, et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med 2011;52:24
39. Scarf AM, Kassiou M. The translocator protein. J Nucl Med 2011;52:677
40. Owen DR, Yeo AJ, Gunn, RN, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 2012;32:1
41. Junck L, Olson JM, Ciliax BJ, et al. PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Ann Neurol 1989;26:752
42. Buck JR, McKinley ET, Hight MR, et al. Quantitative, preclinical PET of translocator protein expression in glioma using 18F-N-fluoroacetyl-N-(2,5- dimethoxybenzyl)-2- phenoxyaniline. J Nucl Med 2011;52:107
43. Tang D, Hight MR, McKinley ET, et al. Quantitative preclinical imaging of TSPO expression in glioma using N,Ndiethyl- 2-(2-(4-(2-18F-fluoroethoxy) phenyl)-5,7-dimethylpyrazolo [1,5-a]pyrimidin-3-yl)acetamide. J Nucl Med 2012;53:287
44. Chen Y, Sajjad M, Wang Y, et al. TSPO 18 kDa (PBR) targeted photosensitizers for cancer imaging (PET) and PDT. ACS Med Chem Lett 2011;2:136